Skip to main content
N

NEUREN PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · NEU ISIN · NZNEUE0001S8 LEI · 984500E48D0FDEE7CE63 ASX Professional, scientific and technical activities
Open in API
Filings indexed 164 across all filing types
Latest filing 2026-04-23 Annual Report
Country NZ New Zealand
Listing ASX NEU

About NEUREN PHARMACEUTICALS LIMITED

https://www.neurenpharma.com/

Neuren Pharmaceuticals Limited is a biopharmaceutical company focused on developing innovative therapies for rare neurodevelopmental disorders. The company's lead product, trofinetide (marketed as DAYBUE), is the first treatment approved by the U.S. Food and Drug Administration for Rett syndrome in both adult and pediatric patients. Neuren is also advancing its second clinical-stage candidate, NNZ-2591, which is being evaluated in Phase 2 clinical trials for multiple serious conditions, including Phelan-McDermid, Angelman, Pitt-Hopkins, and Smith-Magenis syndromes. The company's research centers on synthetic analogs of naturally occurring molecules that regulate brain function, aiming to address significant unmet medical needs in patients with complex neurological impairments through rigorous clinical development and strategic commercial partnerships.

Recent filings

Filing Released Lang Actions
2025 Annual Report to shareholders 68 pages 6.2MB
Annual Report Classification · 1% confidence The document is explicitly titled 'ANNUAL REPORT 2025' for Neuren Pharmaceuticals Limited. It contains a comprehensive review of company activities, a Chair and CEO message, detailed financial statements (Consolidated Statement of Profit or Loss, Financial Position, etc.), and an Independent Auditor's Report. It meets all the criteria for a full annual report. FY 2025
2026-04-23 English
Appendix 4G 12 pages 378.2KB
Governance Information Classification · 1% confidence The document is titled “Appendix 4G – Key to Disclosures Corporate Governance Council Principles and Recommendations” and is lodged under ASX Listing Rules 4.7.3 and 4.10.3 alongside the company’s annual report. It provides the corporate governance statement disclosures, board charters, policies, and whether the entity has followed the ASX Corporate Governance Council’s recommendations. It is a standalone governance disclosure form rather than the full annual report or an announcement of its publication, and it focuses exclusively on governance practices, roles, and policies. This matches the Governance Information category (CGR).
2026-04-23 English
Notice of Annual General Meeting/Proxy Form 23 pages 1.4MB
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal Notice of Annual Shareholders’ Meeting for Neuren Pharmaceuticals, including the Explanatory Memorandum and proxy form, requesting shareholder votes on resolutions (re-election of directors, auditor remuneration, option grants, constitutional amendments, etc.). It is not the company’s Annual Report (10-K), an earnings release (ER), or management presentation (IP), nor is it the meeting minutes or voting results. It is a solicitation of proxies and information statement for the upcoming AGM. Therefore, it should be classified as a Proxy Solicitation & Information Statement (PSI).
2026-04-23 English
Virtual AGM online guide 5 pages 309.5KB
AGM Information Classification · 1% confidence The document is an Online Meeting Guide for MUFG’s shareholder meeting, providing step-by-step instructions on how to attend the AGM virtually, vote, and ask questions. It does not present financial results, legal proposals, or any formal filings; instead it is meeting materials specifically for the Annual General Meeting. This aligns with the AGM Information category.
2026-04-23 English
Update - Notification of buy-back - NEU 6 pages 18.2KB
Transaction in Own Shares Classification · 1% confidence The document is an ASX Appendix 3C daily buy-back notification for Neuren Pharmaceuticals, detailing on-market share repurchase volumes, prices, and cumulative counts. This is a report of the company buying back its own securities, matching the definition of Transaction in Own Shares (POS).
2026-04-20 English
Update - Notification of buy-back - NEU 6 pages 18.2KB
Transaction in Own Shares Classification · 1% confidence The document is an ASX Appendix 3C daily notification of an on-market share buy-back by Neuren Pharmaceuticals, providing details such as number of securities bought back, prices paid, and remaining capacity. This fits the “Transaction in Own Shares” category (company repurchasing its own shares).
2026-04-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.